Thomas J. Sayers

7.3k citations

104 papers · 5.9k indexed · h-index 45

Immunology top 0.5%
- Immune Cell Function and Interaction 35
- Immunotherapy and Immune Responses 26
- T-cell and B-cell Immunology 17
Oncology top 1%
- CAR-T cell therapy research 14
- Cancer-related Molecular Pathways 7
Hematology top 2%
Cancer Research top 5%
Molecular Biology top 5%
- Cell death mechanisms and regulation 26
- Ubiquitin and proteasome pathways 9
Complementary and alternative medicine
- Phytochemicals and Medicinal Plants 7

Co-authors: William J. Murphy Alan D. Brooks Mark J. Smyth John R. Ortaldo Robert H. Wiltrout Dennis D. Taub C R Carter Anatoli Malyguine
Cited by: Immunology Oncology Hematology
Journals: The Journal of Immunology (25 papers)Cancer Immunology Immunotherapy (6 papers)Journal of Leukocyte Biology (5 papers)
Partner nations: United States Australia Japan

In The Last Decade

Thomas J. Sayers

104 papers receiving 5.7k citations

Peers

Countries citing papers authored by Thomas J. Sayers

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Sayers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Sayers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Sayers more than expected).

Fields of papers citing papers by Thomas J. Sayers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Sayers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Sayers. The network helps show where Thomas J. Sayers may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas J. Sayers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas J. Sayers Line = papers co-authored together Thomas J. Sayers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins Cancer Research ·Poonam Tewary,Alan D. Brooks,Ya-Ming Xu,E. M. Kithsiri Wijeratne,Ashley L. Babyak,Timothy Back,Raj Chari,Christine N. Evans,Curtis J. Henrich,Thomas J. Meyer,Elijah F. Edmondson,Maria Teresa P. de Aquino,Thanigaivelan Kanagasabai,Anil Shanker,A. A. Leslie Gunatilaka,Thomas J. Sayers	2021	12
2	Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity Cancer Research ·Anil Shanker,Samuel T. Pellom,C. Starren,Menaka C. Thounaojam,D Libei,Alan D. Brooks,Hideo Yagita∥,Daniel W. McVicar,William J. Murphy,Dan L. Longo,Thomas J. Sayers	2015	23
3	Impact of dietary components on NK and Treg cell function for cancer prevention Molecular Carcinogenesis ·Gustavo Fossati,Thomas J. Sayers,Nancy H. Colburn,John A. Milner,Howard A. Young	2015	15
4	Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma BMC Cancer ·Robert J. Canter,Erik Ames,Veronica Mabel Villarreal Espinosa,Steven K. Grossenbacher,Mingyi Chen,Chin-Shang Li,Dariusz Borys,Rachel Smith,Chen Bingzhen,Thomas J. Sayers,Arta M. Monjazeb,William J. Murphy	2014	20
5	A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells SLAS DISCOVERY ·Lesley Mathews,Jonathan M. Keller,Bonnie L. Goodwin,Rajarshi Guha,Paul Shinn,Timur M. Batrudinov,Craig J. Thomas,D Libei,Thomas J. Sayers,Marc Ferrer	2012	27
6	Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex Molecular Cancer Research ·Alan D. Brooks,Kristen M. Jacobsen,Wenqing Li,Anil Shanker,Thomas J. Sayers	2010	54
7	Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity Cancer Research ·Anil Shanker,Alan D. Brooks,Kristen M. Jacobsen,John W. Wine,Robert H. Wiltrout,Hideo Yagita∥,Thomas J. Sayers	2009	38
8	Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors The Journal of Immunology ·Tahira Khan,Jimmy K. Stauffer,R. H. Williams,Julie A. Hixon,Rosalba Salcedo,Anđelka Tonejc,Timothy Back,Douglas Powell,Stephen Lockett,Liangkang Lv,Thomas J. Sayers,Jon M. Wigginton	2006	30
9	Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy The Journal of Experimental Medicine ·Kazuyoshi Takeda,Noriko Yamaguchi,Hisaya Akiba,Yuko Kojima,Yoshihiro Hayakawa,Jane E. Tanner,Thomas J. Sayers,Naoko Seki,Ko Okumura,Hideo Yagita∥,Mark J. Smyth	2004	165
10	Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis Cancer Immunology Immunotherapy ·Alan D. Brooks,Thomas J. Sayers	2004	32
11	Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing Blood ·Masanobu Komatsu,Michele Mammolenti,Monica Jones,Roland Jurecic,Thomas J. Sayers,Robert B. Levy	2003	27
12	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses The Journal of Immunology ·William J. Murphy,(unknown),Timothy Back,Julie A. Hixon,Jeff Subleski,Naoko Seki,Jon M. Wigginton,Susan E. Wilson,Bruce R. Blazar,Anatoli Malyguine,Thomas J. Sayers,Robert H. Wiltrout	2003	84
13	Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin The Journal of Immunology ·Naoko Seki,Alan D. Brooks,Clive R.D. Carter,Timothy Back,Patricia Blessing,Mark J. Smyth,Robert H. Wiltrout,Thomas J. Sayers	2002	111
14	The Restricted Expression of Granzyme M in Human Lymphocytes The Journal of Immunology ·Thomas J. Sayers,Alan D. Brooks,Jerrold M. Ward,Tomoaki Hoshino,A. Quidor,Gordon Wiegand,Alexsandra Calic,Mark J. Smyth	2001	77
15	IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells The Journal of Immunology ·Jong‐Keuk Lee,Thomas J. Sayers,Alan D. Brooks,Timothy Back,Howard A. Young,Kristin L. Komschlies,Jon M. Wigginton,Robert H. Wiltrout	2000	61
16	The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases Immunogenetics ·Elizabeth Baker,Thomas J. Sayers,Grant R. Sutherland,Mark J. Smyth	1994	27
17	Met-ase: cloning and distinct chromosomal location of a serine protease preferentially expressed in human natural killer cells. The Journal of Immunology ·Mark J. Smyth,Thomas J. Sayers,T A Wiltrout,James C. Powers,Joseph A. Trapani	1993	52
18	Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. Journal of Clinical Investigation ·W J Murphy,Timothy Back,Kevin C. Conlon,Kristin L. Komschlies,John R. Ortaldo,Thomas J. Sayers,Robert H. Wiltrout,DL Longo	1993	38
19	Trafficking and activation of murine natural killer cells: Differing roles for IFN-γ and IL-2 Cellular Immunology ·Thomas J. Sayers,Llewellyn H. Mason,T A Wiltrout	1990	17
20	Regulation of normal myelopoiesis and chronic myelogenous leukaemia' cell proliferation through a non-cytotoxic mechanism by a γ/δ T cell clone☆ Immunology Letters ·Graham Pawelec,Thomas J. Sayers,F.W. Busch	1989	5

About Thomas J. Sayers

Thomas J. Sayers is a scholar working on Immunology, Oncology, Complementary and alternative medicine, Hematology and Molecular Biology, having authored 104 papers that have together received 5.9k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (35 papers), Cell death mechanisms and regulation (26 papers), Immunotherapy and Immune Responses (26 papers), T-cell and B-cell Immunology (17 papers), CAR-T cell therapy research (14 papers), Ubiquitin and proteasome pathways (9 papers), Cancer-related Molecular Pathways (7 papers) and Phytochemicals and Medicinal Plants (7 papers). The work is most often cited by research in Immunology (3.1k citations), Oncology (1.7k citations), Hematology (619 citations), Cancer Research (506 citations) and Molecular Biology (2.2k citations). Thomas J. Sayers has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include William J. Murphy, Alan D. Brooks, Mark J. Smyth, John R. Ortaldo, Robert H. Wiltrout, Dennis D. Taub, C R Carter, Anatoli Malyguine, Naoko Seki and Curtis J. Henrich. Their work appears in journals such as The Journal of Immunology, Cancer Immunology Immunotherapy, Journal of Leukocyte Biology, Immunology Letters and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact